Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2002-09-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.192461099PMID 12218188PMCID PMC129438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

  2002cited by this paper
• ICOS is essential for effective T-helper-cell responses

  2001cited by this paper
• Targeting of Tumor Cells for Human γδ T Cells by Nonpeptide Antigens1

  2001cited by this paper
• PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.

  2001cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• The shared tumor‐specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

  1998cited by this paper
• Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

  1998cited by this paper
• The emerging role of CTLA-4 as an immune attenuator.

  1997cited by this paper
• Serological analysis of human tumor antigens: molecular definition and implications.

  1997cited by this paper
• Cancer vaccines based on the identification of genes encoding cancer regression antigens.

  1997cited by this paper
• The Complexities of T‐Cell Co‐stimulation: CD28 and Beyond

  1996cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone.

  1996cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

  1995cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• Tumor antigens recognized by T lymphocytes.

  1994cited by this paper
• The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

  1991cited by this paper

• Next generation CAR-T cells to tackle down solid tumors.

  2026cites this paper
• Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles.

  2026cites this paper
• T‐Cell Immunity and Lung Cancer

  2026cites this paper
• Functionalized graphene oxide nanoplatform for synergistic photothermal-immunotherapy via targeted siPD-L1 delivery in triple-negative breast Cancer

  2026cites this paper
• Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial

  2026cites this paper
• Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cells

  2026influential citation
• Safe and Efficient CRISPR Genome Editing of Primary Human T Cells Using a Droplet-Based Cell Mechanoporation Platform.

  2026cites this paper
• The Application of PD‐1 Inhibitors in Immunotherapy for Glioblastoma

  2026cites this paper
• Deciphering the Heterogeneity of Pulmonary Macrophages in Response to Fine Particles.

  2026cites this paper
• Active aldehydes accelerate CD8+ T cell exhaustion by metabolic alteration in the tumor microenvironment

  2026cites this paper
• Crosstalk between protein lipidation and ubiquitination in tumor biology

  2026cites this paper
• Survival Benefit of Immunotherapy in Patients With Stage IV Microsatellite Stable Rectal Cancer: A Propensity-Score Matched Analysis.

  2026cites this paper
• Metabolomic profiling reveals the potential of fatty acids as regulators of exhausted CD8 T cells during chronic viral infection.

  2026cites this paper
• Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF/siPD-L1 for enhanced tumor immunotherapy

  2026cites this paper
• Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma.

  2026cites this paper
• Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy

  2026cites this paper
• Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.

  2026cites this paper
• The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications

  2026cites this paper
• MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

  2026cites this paper
• Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

  2026cites this paper
• Analysis of PD-L1 Transcriptional Activity by Chromatin Immunoprecipitation.

  2026cites this paper
• Flow Cytometry Analysis of IFNγ-Induced PD-L1 Cell Surface Expression in Ovarian Cancer Cells.

  2026cites this paper
• Pyroptosis-inducing nanomedicines: A dual-mode therapeutic framework for apoptosis-resistant lung cancer.

  2026cites this paper
• Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma

  2026cites this paper
• Disrupting Immune Silence: Non-Coding RNAs Targeting the PD-1/PD-L1 Axis in Tumor Immunity

  2026cites this paper
• Dissecting the specificity of sugar code recognition - Unleashing the biomedical potential of galectins by protein engineering.

  2025cites this paper
• Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data

  2025cites this paper
• Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.

  2025cites this paper
• Enhancing gastric cancer prognosis prediction via multi-step multi-modality ensemble survival modeling of HE-stained images and mIHC data

  2025cites this paper
• Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T‐cell responses and anti‐tumor immunity by targeting conventional type 1 dendritic cells

  2025cites this paper
• Neurological adverse events of PD-1/PD-L1 immune checkpoint inhibitors in clinical trials: A meta-analysis

  2025cites this paper
• Targeting immune microenvironment in cervical cancer: current research and advances

  2025cites this paper
• Cardiovascular adverse effects of immunotherapy in cancer: insights and implications

  2025cites this paper
• Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events

  2025cites this paper
• BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis

  2025cites this paper
• IPSC-derived NK cells for immunotherapy and therapeutic perspective (Review)

  2025cites this paper
• Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical evolution of patients with head and neck cutaneous squamous cell carcinoma?

  2025cites this paper
• Evaluation of PD-L1, TERT promoter mutations, and BRAFV600E mutation in poorly differentiated, differentiated high grade thyroid carcinoma and anaplastic carcinoma of the thyroid: our institutional experience

  2025influential citation
• Disparate Roles of Cell–Cell Contact and Cytokine Secretion in an In Vitro Model of the Seminoma Microenvironment

  2025cites this paper
• Application of Immune Checkpoint Inhibitors in Cancer

  2025cites this paper
• Glycosylation as an intricate post-translational modification process takes part in glycoproteins related immunity

  2025cites this paper
• Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of Two Cases

  2025cites this paper
• Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis

  2025cites this paper
• Targeting PD-1 post-translational modifications for improving cancer immunotherapy

  2025cites this paper
• The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy.

  2025cites this paper
• An update on the clinical trial research of immunotherapy for glioblastoma

  2025cites this paper
• Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook.

  2025cites this paper
• Immune-checkpoint inhibitor resistance in patients with cancer

  2025cites this paper
• PDCD1 expression increases at elevated temperatures

  2025cites this paper
• Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis

  2025cites this paper
• High-expression of BCL10 inhibits cell-mediated immunity within the tumor immune microenvironment

  2025cites this paper
• Lung Cancer Immunotherapy Approaches: From Clinical Testing to Future Advances

  2025cites this paper
• Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers.

  2025cites this paper
• A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer

  2025cites this paper
• High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration

  2025cites this paper
• PD-L1 delactylation-promoted nuclear translocation accelerates liver cancer growth through elevating SQLE transcription activity.

  2025cites this paper
• Cytotoxic Anti-tumor Drugs and Tumor-Associated Macrophages Synergistically Surge PD-L1 Expression in Esophageal Squamous Cell Carcinoma

  2025cites this paper
• The impact of peptide surface density on PD-L1 receptor inhibition as a therapeutic strategy for triple negative breast cancer.

  2025cites this paper
• Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella

  2025cites this paper
• DNA repair at the crossroads of tumor immunogenicity and cancer therapy: Harnessing innate and adaptive immune pathways for improved therapeutic outcomes.

  2025cites this paper
• ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.

  2025cites this paper
• Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM

  2025cites this paper
• Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis

  2025cites this paper
• Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer

  2025cites this paper
• Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody

  2025cites this paper
• Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?

  2025cites this paper
• All‐In‐One Magnetic Nanoparticles for Thermo‐Immunotherapy of Malignant Melanoma

  2025cites this paper
• Identification of Pathogenic PD‐1+CD8+ T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjögren Disease

  2025cites this paper
• PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma

  2025cites this paper
• Develop a Deep-Learning Model to Predict Cancer Immunotherapy Response Using In-Born Genomes

  2025cites this paper
• Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA–IIIB NSCLC

  2025cites this paper
• Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3, and STAT1 in ovarian cancer cells

  2025cites this paper
• Unlocking the Promise of Antitumor Hyperthermia‐Immunotherapy with Spiky Surface Topology

  2025cites this paper
• Characterization of single neurons reprogrammed by pancreatic cancer

  2025cites this paper
• Ancestry-Specific DNA Damage Repair Gene Mutations and Prostate Cancer

  2025cites this paper
• The past, the present and the future of immune checkpoints inhibitors in multiple myeloma

  2025cites this paper
• AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity

  2025cites this paper
• Lenvatinib enhances antitumor immunity of anti-PD-1 antibody

  2025cites this paper
• Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy

  2025cites this paper
• The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

  2025cites this paper
• Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy

  2025cites this paper
• A novel deep learning framework for automatic scoring of PD-L1 expression in non-small cell lung cancer

  2025cites this paper
• Targeting glycolysis in esophageal squamous cell carcinoma: single-cell and multi-omics insights for risk stratification and personalized therapy

  2025cites this paper
• Drug functional remapping: a new promise for tumor immunotherapy

  2025cites this paper
• Anti-inflammatory effects of immunotherapy in clinical treatment and its potential mechanism in alleviating sleeping disorders: A systematic bibliometric study

  2025cites this paper
• The Prognostic Value and Immunomodulatory Role of Spsb2, a Novel Immune Checkpoint Molecule, in Hepatocellular Carcinoma

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Patterns of pembrolizumab use for recurrent cervical cancer.

  2025cites this paper
• mRNA and protein expression of programmed cell death-ligand-1 on canine mammary gland tumour in dogs of Chiang Mai, Thailand

  2025cites this paper
• Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles

  2025cites this paper
• Cancer-associated fibroblasts gene signature: a novel approach to survival prediction and immunotherapy guidance in colon cancer

  2025cites this paper
• Biomarkers in Cervical Squamous Neoplasia: Diagnostic, Prognostic, and Predictive.

  2025cites this paper
• [Regulation of myeloid-derived suppressor cells by glutamate].

  2025cites this paper
• The Spatial Proximity of CD8+ FoxP3+PD-1+ Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer

  2025cites this paper
• Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells

  2025cites this paper
• Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis

  2025cites this paper
• B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

  2025cites this paper
• Dual generation of stereo- and linear-specific monoclonal antibodies through B-cell receptors by DNA and cell immunization for therapeutic applications.

  2025cites this paper
• miR-28: A Tiny Player in Cancer Progression and Other Human Diseases

  2025cites this paper
• ORAL TOXICITIES ASSOCIATED WITH IMMUNOTHERAPY AND TARGETED THERAPY IN CANCER TREATMENT

  2025cites this paper